HC Wainwright Predicts TG Therapeutics FY2026 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for TG Therapeutics in a research note issued to investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn $1.30 per share for the year, up from their prior forecast of $1.28. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2027 earnings at $1.95 EPS, FY2028 earnings at $2.46 EPS and FY2029 earnings at $3.07 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.21). The business had revenue of $192.57 million during the quarter, compared to the consensus estimate of $192.15 million. TG Therapeutics had a return on equity of 119.68% and a net margin of 72.56%.The company’s revenue for the quarter was up 78.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.15 earnings per share.

Several other brokerages have also recently commented on TGTX. Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. JPMorgan Chase & Co. decreased their target price on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Finally, B. Riley Financial upgraded TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $30.09 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The firm has a fifty day moving average price of $29.85 and a 200 day moving average price of $31.48. TG Therapeutics has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The firm has a market cap of $4.78 billion, a price-to-earnings ratio of 10.86 and a beta of 1.87.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Johnson Financial Group Inc. bought a new position in TG Therapeutics during the second quarter valued at $25,000. Danske Bank A S purchased a new position in shares of TG Therapeutics during the 3rd quarter worth about $25,000. Optiver Holding B.V. grew its holdings in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 732 shares during the last quarter. Bessemer Group Inc. raised its position in TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares during the period. Finally, Salomon & Ludwin LLC purchased a new stake in TG Therapeutics in the 3rd quarter worth about $34,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Key TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Record BRIUMVI-driven revenue growth — Q4 total revenue rose ~78% y/y with U.S. BRIUMVI net revenue of $182.7M and full‑year 2025 BRIUMVI sales of ~$594M (≈+90% y/y); management raised BRIUMVI revenue guidance for 2026, underpinning top‑line momentum. TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
• Positive Sentiment: Analyst model upgrades — HC Wainwright raised Q1–Q3 2026 and FY2030 EPS estimates, signaling growing sell‑side confidence in profitability as BRIUMVI scales. Upgrades can support the stock over the coming quarters. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Meaningful pipeline & commercialization catalysts — Investors highlight potential upside from the Phase 3 ENHANCE study (consolidated dosing) and development of a self‑administered subcutaneous BRIUMVI formulation, which could expand addressable market and margins if successful. TG Therapeutics: ‘Strong Buy’ On BRIUMVI’s Massive Growth
• Neutral Sentiment: Company reaffirmed 2026 revenue outlook and held a conference call outlining commercial execution and retention metrics — positive context, but near‑term stock reaction depends on reconciling EPS miss with guidance. TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Big EPS disappointment — Reported EPS of $0.14 vs. consensus ~$0.35 (≈-60% surprise); the profit miss is the main short‑term catalyst for the share decline despite strong revenues. TGTX Q4 Earnings Lag Estimates (Zacks)
• Negative Sentiment: Near-term volatility risk — Large EPS miss increases odds of short‑term selling pressure and gives traders a reason to pare back positions until subsequent quarters show margin improvement or clearer evidence that guidance will be achieved. TG Therapeutics (TGTX) Misses Q4 Earnings Estimates

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.